Sorafenib (Nexavar®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32016000673
English
Authors' recommendations:
Sorafenib (Nexavar®) is recommended for restricted use within NHS Wales in the following circumstances for the treatment of hepatocellular carcinoma: • patients with advanced hepatocellular carcinoma for whom surgical or loco-regional therapies have failed or were not suitable. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. Sorafenib (Nexavar®) is not recommended for use within NHS Wales outside of these circumstances.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/284
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Niacinamide
- Phenylurea Compounds
- Wales
- Carcinoma, Hepatocellular
- Liver Neoplasms
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.